A tablet-based quantitative assessment of manual dexterity for detection of early psychosis.
Transcranial Magnetic Stimulation (TMS)
autism spectrum disorder (ASD)
behavioral marker
first-episode psychosis (FEP)
manual dexterity
schizophrenia
tablet-based assessment
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
04
2023
accepted:
06
06
2023
medline:
12
7
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
epublish
Résumé
We performed a pilot study on whether tablet-based measures of manual dexterity can provide behavioral markers for detection of first-episode psychosis (FEP), and whether cortical excitability/inhibition was altered in FEP. Behavioral and neurophysiological testing was undertaken in persons diagnosed with FEP ( Compared to controls, FEP patients showed slower reaction times and higher errors in Finger Recognition, and more variability in Rhythm Tapping. Variability in Rhythm Tapping showed highest specificity for the identification of FEP patients compared to all other groups (FEP vs. ASD/SCZ/Controls; 75% sensitivity, 90% specificity, AUC = 0.83) compared to clinical NSS (95% sensitivity, 22% specificity, AUC = 0.49). Random Forest analysis confirmed FEP discrimination vs. other groups based on dexterity variables (100% sensitivity, 85% specificity, balanced accuracy = 92%). The FEP group had reduced short-latency intra-cortical inhibition (but similar excitability) compared to controls, SCZ, and ASD. Cerebellar inhibition showed a non-significant tendency to be weaker in FEP. FEP patients show a distinctive pattern of dexterity impairments and weaker cortical inhibition. Easy-to-use tablet-based measures of manual dexterity capture neurological deficits in FEP and are promising markers for detection of FEP in clinical practice.
Sections du résumé
Background
UNASSIGNED
We performed a pilot study on whether tablet-based measures of manual dexterity can provide behavioral markers for detection of first-episode psychosis (FEP), and whether cortical excitability/inhibition was altered in FEP.
Methods
UNASSIGNED
Behavioral and neurophysiological testing was undertaken in persons diagnosed with FEP (
Results
UNASSIGNED
Compared to controls, FEP patients showed slower reaction times and higher errors in Finger Recognition, and more variability in Rhythm Tapping. Variability in Rhythm Tapping showed highest specificity for the identification of FEP patients compared to all other groups (FEP vs. ASD/SCZ/Controls; 75% sensitivity, 90% specificity, AUC = 0.83) compared to clinical NSS (95% sensitivity, 22% specificity, AUC = 0.49). Random Forest analysis confirmed FEP discrimination vs. other groups based on dexterity variables (100% sensitivity, 85% specificity, balanced accuracy = 92%). The FEP group had reduced short-latency intra-cortical inhibition (but similar excitability) compared to controls, SCZ, and ASD. Cerebellar inhibition showed a non-significant tendency to be weaker in FEP.
Conclusion
UNASSIGNED
FEP patients show a distinctive pattern of dexterity impairments and weaker cortical inhibition. Easy-to-use tablet-based measures of manual dexterity capture neurological deficits in FEP and are promising markers for detection of FEP in clinical practice.
Identifiants
pubmed: 37435404
doi: 10.3389/fpsyt.2023.1200864
pmc: PMC10330763
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1200864Informations de copyright
Copyright © 2023 Le Boterff, Rabah, Carment, Bendjemaa, Térémetz, Alouit, Levy, Tanguy, Morin, Amado, Cuenca, Turc, Maier, Krebs and Lindberg.
Déclaration de conflit d'intérêts
MT and PL own shares in Dextrain company (www.dextrain.com) which develops and commercializes solutions for measurement and rehabilitation of manual dexterity. MT, MM, and PL have a patent on the DexTrain manipulandum (WO2020070305A1) and method for evaluating manual dexterity (WO2016184935A2). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Schizophr Bull. 2022 Mar 1;48(2):505-513
pubmed: 34525195
Neuroimage Clin. 2017 Sep 28;17:124-136
pubmed: 29085774
Acta Psychiatr Scand. 2011 Jun;123(6):451-8
pubmed: 21219267
Brain Res Brain Res Rev. 2000 Mar;31(2-3):138-46
pubmed: 10719142
Schizophr Res. 2004 Apr 1;67(2-3):253-9
pubmed: 14984885
Biol Psychiatry. 2002 Jul 1;52(1):24-31
pubmed: 12079727
Nat Commun. 2019 Aug 1;10(1):3454
pubmed: 31371726
Nature. 2010 Nov 11;468(7321):187-93
pubmed: 21068826
Schizophr Res. 2022 Dec;250:152-163
pubmed: 36417817
Neuroimage Clin. 2022;36:103221
pubmed: 36228483
Brain Stimul. 2020 Sep - Oct;13(5):1298-1304
pubmed: 32585356
Front Psychiatry. 2014 Dec 23;5:185
pubmed: 25566104
Schizophr Res. 2000 Oct 27;45(3):245-60
pubmed: 11042442
Neurosci Biobehav Rev. 2018 Mar;86:176-206
pubmed: 29208533
Front Psychiatry. 2018 Mar 26;9:98
pubmed: 29632500
Psychol Med. 2013 Dec;43(12):2547-62
pubmed: 23507081
Schizophr Bull. 2016 Nov;42(6):1326-1333
pubmed: 27566843
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Dec 20;111:110137
pubmed: 33053417
Schizophr Res. 2013 Oct;150(1):3-10
pubmed: 23800613
Eur Arch Psychiatry Clin Neurosci. 2016 Feb;266(1):35-41
pubmed: 25708455
Radiology. 2009 Jan;250(1):212-21
pubmed: 19092095
Schizophr Res. 2019 Aug;210:94-100
pubmed: 31178362
Br J Psychiatry Suppl. 1998;172(33):53-9
pubmed: 9764127
Neuropharmacology. 2013 May;68:202-9
pubmed: 22727823
Psychiatry Clin Neurosci. 2021 Mar;75(3):82-100
pubmed: 33314465
Electroencephalogr Clin Neurophysiol. 1994 Aug;91(2):79-92
pubmed: 7519144
Arch Gen Psychiatry. 2002 Apr;59(4):347-54
pubmed: 11926935
Psychiatry Res Neuroimaging. 2020 Jun 30;300:111067
pubmed: 32298949
Hum Brain Mapp. 2019 Dec 1;40(17):5029-5041
pubmed: 31403239
Schizophr Res. 2021 Feb;228:447-459
pubmed: 33578368
Neuropsychologia. 2011 Apr;49(5):848-857
pubmed: 21256856
Schizophr Bull. 2004;30(2):351-60
pubmed: 15279052
Schizophr Bull. 2013 Jul;39(4):820-9
pubmed: 22892556
Schizophr Bull. 2020 Jan 4;46(1):17-26
pubmed: 30809667
Schizophr Bull. 2016 Mar;42(2):259-61
pubmed: 26773476
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Curr Opin Psychiatry. 2020 May;33(3):212-218
pubmed: 32049766
Brain. 2019 Jul 1;142(7):2149-2164
pubmed: 31099820
J Child Psychol Psychiatry. 2016 Apr;57(4):446-56
pubmed: 26577292
Neuropsychiatr Dis Treat. 2013;9:1393-409
pubmed: 24072973
J Neuroeng Rehabil. 2022 Mar 24;19(1):35
pubmed: 35331273
Schizophr Res. 2017 Mar;181:30-37
pubmed: 27639418
Front Psychiatry. 2014 Aug 06;5:91
pubmed: 25147527
Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Aug;5(8):770-779
pubmed: 32771179
Br J Psychiatry Suppl. 2002 Sep;43:s50-7
pubmed: 12271801
Psychol Med. 2014 Feb;44(3):499-506
pubmed: 23701858
Conscious Cogn. 2006 Jun;15(2):295-309
pubmed: 16182569
Schizophr Bull. 2014 Sep;40(5):1011-21
pubmed: 24080895
Early Interv Psychiatry. 2009 Nov;3(4):289-95
pubmed: 22642732
Psychol Med. 1998 May;28(3):685-92
pubmed: 9626724
Clin Neurophysiol. 2007 Oct;118(10):2207-14
pubmed: 17709293
Transl Psychiatry. 2015 Jul 14;5:e601
pubmed: 26171982
Psychiatry Res. 2012 Aug 30;199(1):12-8
pubmed: 22633156
Nat Rev Drug Discov. 2016 Jul;15(7):485-515
pubmed: 26939910
Biometrics. 1976 Jun;32(2):429-34
pubmed: 953139
Am J Psychiatry. 2005 Jun;162(6):1203-5
pubmed: 15930071
PLoS One. 2020 Apr 22;15(4):e0231669
pubmed: 32320431
Brain. 2020 Apr 1;143(4):1261-1277
pubmed: 32236540
Early Interv Psychiatry. 2009 Nov;3(4):259-65
pubmed: 22642728
Neuropsychopharmacol Rep. 2019 Jun;39(2):72-77
pubmed: 30712295
Front Psychiatry. 2021 Feb 24;12:573905
pubmed: 33716805
Schizophr Res. 2022 Feb;240:92-102
pubmed: 34991043
Front Synaptic Neurosci. 2010 Jun 28;2:26
pubmed: 21423512
Autism Res. 2020 Jun;13(6):885-896
pubmed: 32157824
Schizophr Bull. 2021 Aug 21;47(5):1452-1462
pubmed: 33479738
Schizophr Bull. 2008 Jan;34(1):155-72
pubmed: 17562694
Biol Psychiatry. 2012 Nov 1;72(9):716-24
pubmed: 22621999
Schizophr Res Cogn. 2015 May 08;2(2):78-83
pubmed: 29114456
Front Psychiatry. 2017 Jul 10;8:120
pubmed: 28740470
J Neuropsychiatry Clin Neurosci. 2002 Winter;14(1):72-6
pubmed: 11884658
J Neuroeng Rehabil. 2015 Aug 02;12:64
pubmed: 26233571
Cortex. 2016 Dec;85:1-12
pubmed: 27770667
Transl Psychiatry. 2019 Mar 7;9(1):110
pubmed: 30846682
Schizophr Res. 1991 Dec;6(1):25-30
pubmed: 1786233
World Psychiatry. 2017 Oct;16(3):251-265
pubmed: 28941089
Psychiatry Clin Neurosci. 2014 Jun;68(6):410-7
pubmed: 24920377
Biol Psychiatry. 2012 Nov 1;72(9):744-51
pubmed: 22502988
Clin Neurophysiol. 2016 Aug;127(8):2834-2845
pubmed: 27417060
Eur Arch Psychiatry Clin Neurosci. 2018 Feb;268(1):49-56
pubmed: 28761988
Br J Psychiatry. 1990 Nov;157:735-9
pubmed: 2132562
Brain Stimul. 2014 Mar-Apr;7(2):158-69
pubmed: 24472621
Front Psychiatry. 2019 Apr 11;10:204
pubmed: 31031656
Neuropsychopharmacology. 2017 Jan;42(2):502-511
pubmed: 27461082